Cutiss

About Cutiss

CUTISS AG is a Swiss life science startup specializing in the development of personalized skin technology to treat severe skin defects. The company operates in the healthcare and biotechnology market, focusing on providing innovative solutions for patients suffering from extensive and deep skin injuries. These injuries often require surgical interventions, and existing treatments can leave patients with painful, disfiguring, and debilitating outcomes.

CUTISS AG's core product is denovoSkin, a bio-engineered, personalized human skin graft. This technology is the result of over 15 years of research conducted at the Tissue Biology Research Unit of the University Hospital Zurich. The company has developed a method to produce large quantities of customized skin grafts that can be tailored to each patient's specific needs. This personalized approach aims to offer a safer, more effective, and accessible therapy for both children and adults.

The primary clients of CUTISS AG include hospitals, clinics, and specialized medical centers that treat patients with severe skin defects. The company also collaborates with research institutions and healthcare providers to advance its technology and expand its applications.

CUTISS AG operates on a business-to-business (B2B) model. It generates revenue by selling its personalized skin grafts to medical institutions and healthcare providers. Additionally, the company may engage in partnerships and licensing agreements to further monetize its technology and expand its market reach.

In summary, CUTISS AG is revolutionizing the treatment of severe skin defects with its innovative, personalized skin graft technology. By focusing on the needs of patients and collaborating with healthcare providers, the company aims to improve the quality of life for those affected by severe skin injuries.